Non-rash dermatologic adverse events related to targeted therapies

Abstract

Insights

This review covers non-rash skin side effects from targeted therapies, offering management strategies for xerosis, pruritus, and other conditions. Evidence-based options are limited, but practical recommendations exist for clinical use.

Area of Science:

  • Dermatology
  • Oncology
  • Pharmacology

Background:

  • Targeted therapies have increased, leading to various dermatological adverse events.
  • Non-rash events like xerosis, pruritus, and hand-foot skin reaction are common.
  • These events can significantly impact patient quality of life.

Purpose of the Study:

  • To synthesize background information on non-rash dermatological adverse events.
  • To outline management strategies for these side effects.
  • To provide guidance for clinical practice and nursing.

Main Methods:

  • Literature review of peer-reviewed journal articles.
  • Consultation of professional manuals and online resources.
  • Synthesis of reported adverse events and management recommendations.

Main Results:

  • Numerous dermatological adverse events associated with targeted therapy are reported.
  • Common events include xerosis, skin fissures, pruritus, photosensitivity, and hair/nail changes.
  • Severe events like Stevens-Johnson syndrome and toxic epidermal necrolysis also occur.

Conclusions:

  • Evidence-based treatment options for these adverse events are limited.
  • Numerous practical recommendations are available in the literature.
  • Education, assessment, and management are crucial for enhancing nursing practice and patient care.

Related Concept Videos

Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial...
206
Drug Toxicity: Overview01:00

Drug Toxicity: Overview

Drug toxicity quantifies the harm a compound causes to an organism, varying by dose and potentially impacting whole systems or specific organs like the liver. Toxic reactions may arise from venomous insect or spider bites, with effects ranging from mild symptoms to severe outcomes such as brain damage or death. Common forms of acute poisoning include ethanol intoxication and overdose of pain or fever medications, with substances like GHB and heroin being particularly lethal at doses close to...
291
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.4K
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
229
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81